Skip to main content
AmigoFish

Powering AI-Driven Drug Discovery with President of Isomorphic Labs Max Jaderberg

From No Priors: Artificial Intelligence | Technology | Startups · · 39 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Drug discovery and development has long relied on expensive, time-consuming empirical trial and error. By shifting the discovery process onto computers, Isomorphic Labs wants to fundamentally change medicine from a process of discovery to one of precision engineering. Elad Gil sits down with Isomorphic’s president Max Jaderberg to discuss his vision for using predictive AI models to achieve experimental accuracy. Max details how the success of AlphaFold provided the first proof of concept that a deep learning model could generalize in the field of biology, and how an AI model’s compounding of learnings allows it to achieve generalizability with scale, thus greatly increasing the probability of success as well as speed in real world clinical trials. He also talks about evolving past the need for animal testing through in-silico models, Isomorphic’s focus on developing drug design engines that are agnostic of disease area, target class, and modality, why accurate molecule engineering unlocks the potential for multidrug cocktails that span complex biological pathways, and how he believes AI molecule optimization will improve both human lifespan and healthspan.

Sign up for new podcasts every week. Email feedback to show@no-priors.com

Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @MaxJaderberg | @IsomorphicLabs

Chapters:

00:00 – Trailer

00:45 – Max Jaderberg Introduction

01:24 – Isomorphic Origins

05:23 – Drug Discovery Stagnation

11:49 – Hiring at Isomorphic

14:35 – Bringing Drug Discovery Onto Computers

19:31 – Isomorphic’s Datasets

20:30 – Rethinking Endpoints

22:50 – External vs. Internal Dependences

23:57 – Automating Biologic Labs

26:22 – Internal Development vs. Partnerships

27:19 – Areas of Human Health Focus

29:21 – Multidrug Approaches

32:17 – Risk Appetite Variation

34:26 – Disease Treatment Outlook

35:42 – Human Longevity and Drug Development

39:16 – Conclusion

Back to No Priors: Artificial Intelligence | Technology | Startups · Report a problem